Aprea Therapeutics to Present at Global Investment Conference
Aprea Therapeutics, Inc. (NASDAQ: APRE), a pioneering biopharmaceutical company, focuses on creating innovative cancer treatments that uniquely exploit vulnerabilities in cancer cells while minimizing collateral damage to healthy tissues. This approach allows for more effective and safer therapies that target cancer directly. Today, Aprea announced its participation at the H.C. Wainwright 27th Annual Global Investment Conference.
Event Participation Details
Management will present at the conference taking place in New York from September 8 to 10. Aprea's presentation is scheduled for September 9 at 3:30 PM ET. The event will feature a discussion on the company's ongoing development and future plans. Investors and stakeholders interested in the evolving landscape of cancer therapies won't want to miss this presentation.
Innovative Therapies on the Horizon
Aprea's commitment to addressing the unique challenges posed by cancer is evident in its burgeoning pipeline of therapies. One highlight is APR-1051, an oral inhibitor that targets the WEE1 kinase, a key protein that regulates cell division in cancer cells. This therapy aims to enhance the power of chemotherapeutics and target resistant cancers efficiently.
ATR Inhibitor ATRN-119
Another noteworthy candidate is ATRN-119, a macrocyclic small molecule designed to inhibit ATR, which plays a critical role in DNA damage repair mechanisms found to be exploited by cancerous cells. This drug is currently under clinical evaluation for treating solid tumors, showcasing Aprea's dedication to developing therapies that address significant unmet medical needs in oncology.
Aprea's Unique Approach to Cancer Treatment
The distinct approach taken by Aprea Therapeutics sets it apart from traditional cancer treatments. By targeting specific mutations and weaknesses found in cancer cells, Aprea seeks to improve treatment efficacy while minimizing the adverse effects that often accompany conventional chemotherapy. This strategy not only aims to prolong survival for cancer patients but also enhance their quality of life through fewer side effects.
Company's Vision and Future Directions
Aprea is dedicated to advancing its pipeline and furthering its mission to bring ground-breaking cancer therapies to market. The company leverages cutting-edge research and development to refine its drug candidates, ensuring they meet the needs of equipping healthcare professionals with effective tools against cancer.
Investor Relations and Contact Information
For those interested in more detailed information about the company and its innovative therapies, Aprea maintains an investor relations website where material updates will be provided. Stakeholders and potential investors are encouraged to visit Aprea's website for recent news and events.
How to Reach Aprea Therapeutics
If you have inquiries or need specific information, you can reach out to Mike Moyer at LifeSci Advisors via email. For additional insights and updates, Aprea's investor relations platform is a reliable source for compliance and disclosures.
Frequently Asked Questions
What is Aprea Therapeutics known for?
Aprea Therapeutics specializes in developing unique cancer therapies that specifically target cancer cells while sparing healthy tissues.
When is Aprea's presentation scheduled?
Aprea will present on September 9 at 3:30 PM ET during the H.C. Wainwright Global Investment Conference.
What are some of Aprea's lead drug candidates?
Key candidates include APR-1051 and ATRN-119, which are currently in clinical development.
How can investors learn more about Aprea?
Investors can visit Aprea's investor relations website for recent updates and disclosures.
Who can be contacted for investor inquiries?
Mike Moyer at LifeSci Advisors is the main contact for investor inquiries regarding Aprea Therapeutics.
